Professional Documents
Culture Documents
STOPPFall (Screening Tool of Older Persons
STOPPFall (Screening Tool of Older Persons
STOPPFall (Screening Tool of Older Persons
hor(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society.
doi: 10.1093/ageing/afaa249 All rights reserved. For permissions, please email: journals.permissions@oup.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution
NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits
non-commercial reproduction and distribution of the work, in any medium, provided the original work
is not altered or transformed in any way, and that the work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
RESEARCH PAPER
1
L.J. Seppala et al.
25
Department of Geriatric Medicine, Cork University Hospital, Cork, Ireland and Department of Medicine, University College Cork,
Cork, Ireland
26
Geriatria, Accettazione Geriatrica e Centro di ricerca per l’invecchiamento, IRCCS INRCA, Ancona, Italy.
Abstract
Background: Healthcare professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge
Keywords: accidental falls, fall-risk-increasing drugs, deprescribing, aged, adverse effects, older people
Key Points
• There is no consensus on which medications are considered as fall-risk-increasing drugs despite several systematic reviews.
• STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) was built through a Delphi
process.
• The STOPPFall is more comprehensive than most national falls prevention guideline listings.
• It can provide a first step towards harmonising the practice and guidelines on drug-related falls in Europe.
• The STOPPFall has been combined with a practical deprescribing tool designed to assist in clinical decision-making.
2
STOPPFall
medication classes and falls to have sufficient statistical power European expert panel and International advisory
[5]. Secondly, as most studies do not focus on investigating board
individual treatment effects, more work is warranted to In total, 24 members EuGMS Task and Finish Group on
facilitate personalised drug optimization. FRIDs and Special Interest Group (SIG) on Pharmacology
Currently, several explicit prescribing tools including accepted the invitation to participate in the Delphi
STOPP/START (Screening Tool of Older Persons poten- process and to fill in an additional deprescribing tool ques-
tially inappropriate Prescriptions/Screening Tool to Alert tionnaire [5,26,27]. A non-European international advisory
doctors to Right Treatment), Beers criteria, FORTA (Fit board was established consisting of experts on geriatric
fOR The Aged)-list and TIME (Turkish Inappropriate pharmacotherapy.
Medication use in the Elderly) are available to guide
3
L.J. Seppala et al.
Figure 1. Distributions of level of agreements for the medication classes included in the STOPPFall and for the classes that reached
no consensus.
4
STOPPFall
Table 1. Statements about possible risk differences within the pharmacological classes that reached consensus
Antipsychotics • Risk difference is related to variation in (i) sedative, (ii) anticholinergic and (iii) alpha-receptor properties
Opioids • Strong opioids are more fall-risk-increasing than weak opioids
Antidepressants • Tricyclic antidepressants (TCA’s) are more fall-risk-increasing than others
• Risk difference is related to the variation in (i) sedative effects, (ii) propensity to cause orthostatic
hypotension and (iii) anticholinergic activity
Anticholinergics • Medications with high anticholinergic activity are more fall-risk-increasing than weak anticholinergics
Antiepileptics • Older generation antiepileptics are more fall-risk-increasing than newer antiepileptics
• Risk difference is related to the variation in sedative effects
Diuretics • Loop diuretics are more fall-risk-increasing than other diuretics
Alpha-blockers for benign prostatic hyperplasia • Non-selective alpha-blockers are more fall-risk-increasing than selective
5
L.J. Seppala et al.
the section of ‘drugs that predictably increase the risk of falls vention. In STOPP/START version 2, only benzodiazepines,
in older people’ in STOPP/START so that in general, the neuroleptics, vasodilators with persistent postural hypoten-
STOPPFall could be expected to be more suited for falls pre- sion and Z-drugs are mentioned under the FRIDs section.
6
STOPPFall
Furthermore, a consensus was reached for 18 statements agents was identified by the Task and Finish Group as a
concerning differences in the fall-risk-increasing properties gap in the current literature [5]. The panellists frequently
within pharmacological classes. The lack of knowledge of identified variation in sedative effects, anticholinergic
the risk related to pharmacological subclasses and individual activity and propensity to cause orthostatic hypotension as
7
Downloaded from https://academic.oup.com/ageing/advance-article/doi/10.1093/ageing/afaa249/6043386 by guest on 30 April 2021
L.J. Seppala et al.
Figure 2. Continued.
8
STOPPFall
features causing differences in medication-related falls risk. Future research and clinical implications
These differences emphasise the need for critically evaluating Since panellists could not reach consensus on 17 medication
the choice of individual agents when prescribing FRIDs. classes regarding whether they should be classified as
Moreover, to gain further insights into these risk differences, FRIDs, it is apparent that more research is warranted in
the evaluation of specific pharmacological agents should the future. Firstly, only a few studies have investigated
be a key item in the future FRIDs research agenda. Such falls risk related to several of these medication classes
studies will enable the identification of safer prescription to date. Secondly, considering the quality issues in the
alternatives. published observational studies including medication
It has been reported that deprescribing can be performed and falls ascertainment and controlling for confounding,
safely in older people [29]. However, despite the growing advocating better research quality is important. Another
evidence on falls as an adverse drug reaction, deprescribing explanation for lack of consensus could be heterogeneous
FRIDs is often difficult and infrequently performed [5]. treatment effects due to different patient characteristics.
To support healthcare professionals in their decision- Disentangling a single drug effect in the context of drug–
making, we developed a practical deprescribing tool, drug interactions and drug–disease interactions is difficult,
including important components of the deprescribing given the multiple causes for a fall and high prevalence
process [28]. This practical guide can help overcome current of polypharmacy in older patients. Furthermore, it is
reluctance in clinical practice by providing an up-to-date challenging to label these medication classes, such as beta-
and straightforward source of expert knowledge. However, blockers, as purely FRIDs as they have known benefits
for successful implementation, national dissemination regarding prevention of cardiovascular disease and symptom
of this tool among healthcare professionals is essential. improvement. Thus, investigating heterogeneous treatment
The Task and Finish Group members intend to take a effects and attempts to identify the older persons at risk
role in this spread of knowledge e.g. through national of medication-related falls are necessary to gain improved
conferences, seminars and webpages. A link to the online insight. Furthermore, assessing effect of dosages, combina-
decision trees is available at the Task and Finish Group tion therapies and drug–drug interactions on falls risk was
webpage [30]. Finally, patient-centred care has been found beyond the scope of this study and should be addressed in
to improve patient satisfaction, adherence, quality of life the future.
and overall health outcomes [28]. Therefore, patients The EuGMS supports the use of STOPPFall as a screen-
should be engaged throughout the process and their ing tool to identify FRIDs when performing a medication
personalised needs and concerns should be taken into review in older fallers. Also, in accordance with our position
account [28,31]. paper, we recommend systematically checking for a history
9
L.J. Seppala et al.
10
STOPPFall
3. Seppala LJ, Wermelink A, de Vries M et al. Fall-risk-increasing 18. O’Mahony D, O’Sullivan D, Byrne S et al. STOPP/START
drugs: a systematic review and meta-analysis: II. Psychotrop- criteria for potentially inappropriate prescribing in older peo-
ics. J Am Med Dir Assoc 2018; 19: 371 e11–7. ple: version 2. Age Ageing 2015; 44: 213–8.
4. Seppala LJ, van de Glind EMM, Daams JG et al. Fall-risk- 19. American Geriatrics Society. American Geriatrics Society
increasing drugs: a systematic review and meta-analysis: III. 2015 updated beers criteria for potentially inappropriate
Others. J Am Med Dir Assoc 2018; 19: 372 e1–8. medication use in older adults. J Am Geriatr Soc 2015; 63:
5. Seppala LJ, van der Velde N, Masud T et al. EuGMS task and 2227–46.
finish group on fall-risk-increasing drugs (FRIDs): position on 20. Pazan F, Wehling M. The FORTA (fit fOR the aged) app as a
knowledge dissemination, management, and future research. clinical tool to optimize complex medications in older people.
Drugs Aging 2019; 36: 299–307. J Am Med Dir Assoc 2017; 18: 893.
6. Laflamme L, Monarrez-Espino J, Johnell K et al. Type, num- 21. Bahat G, Ilhan B, Erdogan T et al. Turkish inappropriate
11